[
    [
        {
            "time": "2021-07-18",
            "original_text": "孙飘扬再出山背后：PD-1增长已至尾声，恒瑞医药将迎至暗时刻",
            "features": {
                "keywords": [
                    "孙飘扬",
                    "PD-1",
                    "恒瑞医药",
                    "增长尾声",
                    "至暗时刻"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "孙飘扬再出山背后：PD-1增长已至尾声，恒瑞医药将迎至暗时刻",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-07-18",
            "original_text": "恒瑞医药(600276.SH)：注射用甲苯磺酸瑞马唑仑、注射用HRS3797获批临床试验",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "甲苯磺酸瑞马唑仑",
                    "HRS3797",
                    "临床试验"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)：注射用甲苯磺酸瑞马唑仑、注射用HRS3797获批临床试验",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-07-18",
            "original_text": "医药行业周报：中报预告落地 个股表现持续分化",
            "features": {
                "keywords": [
                    "医药行业",
                    "中报预告",
                    "个股分化"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业周报：中报预告落地 个股表现持续分化",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-07-18",
            "original_text": "恒瑞医药：子公司收到两项药物临床试验批准通知书",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "子公司",
                    "临床试验",
                    "批准通知书"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：子公司收到两项药物临床试验批准通知书",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-07-18",
            "original_text": "恒瑞医药：子公司药品获批开展临床试验",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "子公司",
                    "药品",
                    "临床试验"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：子公司药品获批开展临床试验",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-07-18",
            "original_text": "恒瑞医药：子公司收到注射用甲苯磺酸瑞马唑仑、注射用HRS3797的药物临床试验批准通知书",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "子公司",
                    "甲苯磺酸瑞马唑仑",
                    "HRS3797",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：子公司收到注射用甲苯磺酸瑞马唑仑、注射用HRS3797的药物临床试验批准通知书",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]